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One of the main components of the drug supply of the country's population with medicines is 
public procurement, which at the legislative level implements the principle of universal access to 
medical care and guarantees the quality of medical services provided. The authors analyzed the 
system of public procurement of medicines in Russia: the main sources of financing, customers 
and suppliers, territorial distribution, structure of methods of placing state orders are determined. 
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Uno de los principales componentes de la oferta de medicamentos de la población del país es la 
contratación pública, que a nivel legislativo implementa el principio de acceso universal a la 
atención médica y garantiza la calidad de los servicios médicos brindados. Los autores analizaron 
el sistema de contratación pública de medicamentos en Rusia: se determinan las principales fuentes 
de financiación, clientes y proveedores, distribución territorial, estructura de los métodos de 
realización de pedidos estatales. 
 
Palabras clave: medicamentos (preparados), sistema de salud, sistema de contratación pública, 




The public procurement segment is one of the components of the pharmaceutical market in Russia, 
which is very predictable and stable. Financing of this type of procurement mainly comes from the 
funds of compulsory medical insurance (MHI). The main purpose of the contract system in the 
conclusion of public procurement is transparency and openness of the entire procedure for placing 
and executing a state contract, for which a single publicly accessible information system, a register 
of concluded contracts and unfair suppliers has been created. The process of preparation and 
implementation of state contracts is aimed at ensuring that it is impossible to carry out any actions 
that contradict the mandatory legislative norms of the Russian Federation, by participants in 
procurement activities, including the inability of planning and implementing actions that contradict 
legislative acts. 
 
The system of drug supply of municipal health care institutions is regulated by Federal 
Law No.44 "On the contract system in the field of procurement of Goods, Works, and Services for 
state and municipal needs" and Federal Law No.223 "On procurement of Goods, Works, and 
Services by certain types of legal entities", which are the starting point for specific regulation of 
various relations related to drug supply issues. 
 
The state supports domestic manufacturers by purchasing medicines, necessary equipment 
and medical products for institutions that are part of the healthcare system through state contracts, 
promoting competition and the development of innovative technologies. The role of the State in 




The methodological basis of the study is a set of measures of scientific knowledge, including 
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In modern conditions, the pharmaceutical market in Russia is represented by two segments: 
commercial and state. The commercial market of pharmaceutical products is engaged in the sale of 
medicines through pharmacy chains, without taking into account sales carried out under the 
Program of Additional Drug provision. It should be noted that in 2019 there was an increase in the 
commercial market of medicines by 3.0%, amounting to 1,021.1 billion rubles. In total, the 
consumption of medicines in 2019 through the pharmacy network reached 5.1 billion rubles. 
packaging, which is 1.9% less than in 2018. 
 
The state market of pharmaceutical products is engaged in providing medicines through 
pharmacy chains not only under the Program of additional Drug provision, regional benefits, but 
also sells medicines through medical and preventive institutions. 
 
Therefore, according to paragraph 1 of Article 4 of the Federal Law of 12.04.2010 No.61 
"On circulation of Medicinal Products", pharmaceutical substances and medical preparations are 
considered to be medicinal products. Only pharmaceutical products that are registered in the state 
register are recognized as medicines that are allowed for use in the treatment of patients. 
 
Medical institutions can purchase medicines from both manufacturers and wholesale 
organizations of medicines or pharmacies. Also, medical institutions have the right to receive 
medicines for supply centrally. 
 
Medicines sold wholesale should be included in the state register. The seller of medicines, 
as a wholesale seller, must have a license for pharmaceutical activities (with the indication 
"wholesale of pharmaceutical products"). In addition, the wholesale sale of medical products must 
comply with the Rules of Good Distribution Practice within the framework of the Eurasian 
Economic Union, approved by the decision of the Council of the Eurasian Economic Commission 
No. 80 of 03.11.2016. 
 
Medicines are one of the most problematic purchases under Federal Law No.44 and 
Federal Law No.223. The share of purchases under Federal Law No.44 in 2019 is 86%, while 
Federal Law No.223 accounts for 14%. 
 
Table 1. Completed auctions 
 
Year 
Federal Law No.223 Federal Law No.44 
billion RUB % billion RUB % 
2015 53,2 14,3% 0,2 0,3% 
2016 156,7 30,6% 0,5 1,6% 
2017 61,2 14,2% 19,4 4,5% 
2018 81,5 16,8% 26,2 5,4% 
2019 84,9 14% 515, 86% 
 
In 2019, more than 481 thousand orders for the purchase of medicines were published for 
the needs of medical institutions, which is 17% higher than in 2018. The number of cancelled 
tenders increased from 75 to 121 thousand auctions (by 60%), the number of completed auctions – 
by 1%. The share of completed auctions was 70% of the total number of bids, which is 
significantly less than in 2018 (81%). The share of canceled applications in 2019 increased from 
18% to 25%. In general, the number of completed tenders has not changed significantly over the 
past 5 years. 
 
The main method of placing orders under Federal Law No.44 in 2019 is an electronic open 
auction with a share of 92%, while under Federal Law No.223 the most frequently used method is 
to request quotations (40%) and purchase from a single supplier (34%). The share of auctions 
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remaining at the stages of placement "commission work" remains quite high, which is associated 
with failed tenders. 
 
Table 2. Stages of placing an order 
 













Work of the commission, 
submission of 
applications 
582 323 250 3 676 22 447 
Placement completed 288 037 324 061 320 325 334 061 338 406 
Placement canceled 49 698 54 220 43 920 75 334 120 656 
Total auctions 338 317 378 604 364 395 413 071 481 509 
 
In monetary terms, the share of cancelled tenders in 2019 increased significantly compared 
to 2018. This is due to the fact that most of the tenders cancelled in April-June 2019 were re-drawn 
from August to September. For 63.5 thousand published schedule plans with the sum of 51.3 
billion rubles - it was not possible to place an order, but for 5.6 thousand of them - more than one 
order placement was carried out. 
 
Despite a small difference in the number of completed auctions (1%) in 2019, the total 
amount of purchases of medicines increased by 20% and amounted to 578 billion rubles on the 
winner's prices. 
 
In 2019, according to the completed auctions for the purchase of medicines, the difference 
between the sum of the winners ' prices (578 billion rubles) and the sum of the initial maximum 
prices declared in the documentation (601 billion rubles) was 3.3%. 
 







Completed auctions Increase in the 
volume of played 
trades  
(to the previous 
year), % 
The volume of 
auctions, the 
price of the 
order, 
billion RUB 
The volume of 
auctions, the price 





2015 338 316 373,0 342,3 - 8,2 - 
2016 378 605 511,6 466,4 - 8,8 + 26,6 
2017 364 394 431,3 384,5 - 10,9 - 21,3 
2018 413 072 488,5 457,8 - 6,3 +16,1 
2019 481 509 600,8 578,3 - 3,7 + 20,9 
 
A sharp increase in the volume of drawn trades in 2016 compared to 2015 is due to the fact 
that there was a procedural change in trading conducted under the law Federal Law No.223, which 
began on January 1, 2017. In this regard, those customers who previously worked under Federal 
Law No.223, until the beginning of 2017, required to either publish or draw the largest number of 
auctions. In 2017, the expectations of bidders were not met and the previous trend of annual 
growth remained. 
 
In 2019, the total amount of purchases of medicines increased significantly and amounted 
to 20.9%, reaching 578.3 billion rubles. Moreover, the difference between the sum of the winners ' 
prices and the sum of the initial maximum prices was 3.7%. 
 
According to the type of lot, most of the tenders belong to the category of "Monolot", i.e. a 
lot containing a single international non-proprietary name. In recent years, there has been a clear 
trend towards a gradual increase in the share of "Monolots". At the same time, since 2013, the 
structure of lots is gradually and steadily changing towards single-position lots. In 2012, the share 
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of multi-item lots prevailed, i.e. lots that contain several dosage variations for one international 
nonproprietary name or several international nonproprietary names. In 2013, single-position 
pillboxes are played in less than half of the cases, and since 2014, the share of single-position lots 
increases every year and accounts for more than half of all lots. 
 
Table 4. The type and structure of lots 
The lot type 2015 2016 2017 2018 2019 
Monolot 66,0% 69,1% 73,2% 74,2% 74,9% 
Mixed lot 34,0% 30,9% 26,8% 25,8% 25,1% 
The structure of the lot      
Single-position 53,8% 57,0% 61,6% 64,0% 65,3% 
Multi-position 46,2% 43,0% 38,4% 36,0% 34,7% 
Total lots 288 037 324 061 320 225 334 061 338 406 
 
If we talk about the method of placing an order on the tender market, we can distinguish 
such as: open auction, request for quotations and purchase from a single supplier. The most 
commonly used method of public procurement is an electronic open auction. It accounted for: in 
2015 - 85.6%, in 2016-71.9%, in 2017-77.3%, in 2018 and 2019-76% and 83.2%, respectively, of 
the total volume of public procurement. In 2016, only 72% of the total volume of orders were 
placed through an electronic open auction in monetary terms, which is due to a significant increase 
in the request for quotations as a form of bidding under Federal Law No.223 (minimum value), 
and in 2019, open auctions as a form of procurement increased to 83%. Purchases from a single 
supplier over the past five years have been fairly stable and account for 10%. 
 
Table 4. Methods of placing orders 
 
 


















Open auction in electronic form 318,2 359,8 333,0 371,3 499,3 
Purchasing from a single supplier 16,8 40,1 41,8 49,1 61,1 
Request for quotations, offers 36,4 92,3 27,0 45,1 38,2 
Special investment contract - - 28,9 22,6 1,7 
Other - 7,9 - - - 
 
The share of purchases under Federal Law No.44 has been stable at 85-86% over the past 
years, while the share of purchases under Federal Law No.223 is 14-15%. According to Federal 
Law No.44, the main method of placing orders is an open auction in electronic form - 92%, while 
other methods are more often used under Federal Law No.223: request for quotations - 40% and 
purchase from a single supplier-34%. 
 
From 2013 to 2018, purchasing activity within the framework of the " National 
Immunisation Schedule" is gradually increasing. The volume of purchases under the vaccine 
prevention program during this period increased more than fourfold: from 4.5 billion rubles in 
2013 to 22 billion rubles in 2019, despite the fact that in 2018 there was a slight decrease in 
volumes to 13.3 billion rubles in prices of the winners. 
 
Table 5. Procurement category for completed auctions 










Hospital purchases 111,6 119,7 126,7 149,7 218,8 
Preferential purchases 118,2 138,8 148,4 185,4 207,9 
Federal program "7(12) 43,4 39,1 45,9 62,0 84,1 
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Federal target program            " 
vaccinal prevention " 
8,1 10,3 15,1 13,3 21,8 
Federal target program " 
Hepatitis B, C/HIV» 
- - 24,7 24,3 26,4 
Other 61,0 158,5 23,7 23,0 19,5 
 
According to the results of 2019, we can talk about an increase in purchases of medicines 
under the Federal Program "7/12 nosologies" (at the end of 2018, 12 nosologies were included in 
this program). Public procurement under this program in 2017 amounted to 44-46 billion rubles 
after a decrease in 2016; in 2018 the financing of the program increased, which affected an 
increase of 35%, reaching 62 billion rubles. This trend continued in 2019, reaching 84 billion 
rubles with an increase of 36%. 
 
In 2017, purchases of antiretroviral drugs "Federal Target Program Hepatitis B, C/HIV" 
were allocated to a separate category; in 2019, the volume of purchases remained approximately at 
the level of 2017-2018 (26 billion rubles). 
 
In 2019, the clinical segment and the segment working with preferential medicines showed 
positive growth in market volumes. Clinical purchases increased by 46%, and purchases of 
concessional medicines - by 12%. The increase in the clinical segment can be explained by the fact 
that part of the purchases of cancer drugs was transferred to the medical and preventive institutions 
themselves, with their subsequent financing from the Federal Compulsory Health Insurance Fund 
under certain conditions. 
 
The source of funding for these types of orders for the period from 2016 to 2019 is the 
"Federal Budget", with an increase in funding by 11% from 141 billion rubles in 2018 to 157 
billion rubles in 2019. 
 




Sources of funding, 
the price of the winner 














92,6 32,6 84,4 24,8 128,1 36,4 140,9 31 156,8 27 
The regional 
budget 





43,8 15,4 48,1 14,2 43,9 12,5 54,29 12 81,3 14 
Funds of the 
budget institution 
39,4 13,9 68,5 20,2 51,6 14,6 68,2 15 86,0 15 
Municipal budget 17,0 6 42,6 12,5 17,2 4,9 18,5 4 2,9 -1 
Inter-budget 
transfers 




10,5 3,7 12,9 3,8 10,2 2,9 9,6 2 10,2 2 
No other source 
of funding is 
specified 
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The number of purchases and their volume at the expense of the regional budget and the 
Federal Compulsory Medical Insurance Fund (FFOMS) increased significantly – by 54% from 
both sources. Also, these channels have increased their share in the total distribution of funds – 
25% in the regional budget, in 2018 this figure was 21%, and 14% in FFOMS against 10.5% in 
2018. The share of municipal budgeting in 2019 decreased and showed a negative trend of -1% 
compared to the indicators of 2018. 
 
If we consider financing by federal districts, the largest part of state financing takes place 
in the Central Federal District with an indicator of 48% of the total volume of orders. This is due to 
the fact that funding for federal programs of preferential provision of medical products and central 
military hospitals is located in the Central Federal District, including Moscow and the Moscow 
Region. 
 
At the same time, regional funding from the respective budgets is most actively carried out 
in the North-Western Federal District with a share of 39%, the Far Eastern and Ural Federal 
Districts with a share of 36% in each, the smallest share of regional funding from the regional 
budget falls on the Volga District with a share of 21%. This situation in the Volga region is 
associated with the main purchases of medicines in Nizhny Novgorod, carried out through the 
regional pharmacy with a share of 38%. A similar situation is observed in other regions, such as 
Tatarstan and the Krasnoyarsk Territory. Funding from the Federal Compulsory Medical Insurance 
Fund (FFOMS) is carried out in the Southern Federal District with a share of 36% and in the North 
Caucasus Federal District with a share of 35% and in the Far East with 33%, respectively. It 
should be noted that other sources of financing are practically not used in the North Caucasus 
Federal District and they account for only 3%. The same situation is observed in the Siberian 
Federal District with a 3% share of other financing. 
 
From 2016 to 2019, more than 11 thousand different customers participated in tendering 
for the supply of medicines, in 2019 there were slightly more than 8.5 thousand customers. 
Collectively, the 50 largest customers accumulate 60% (337 billion rubles) of the total budget 
supply of medicines in Russia. 
 




The price of the 
winner, billion 
RUB 
1.  Ministry of Health of the Russian Federation 138,9 
2.  
State Institution of the City of Moscow "Procurement Agency 
(Contract Service) of the Moscow Department of Health" 
47,2 
3.  National Immunobiological Company “Nacimbio” JSC 23,1 
4.  Ministry of Health of the Moscow Region 16,8 
5.  State enterprise of Nizhny Novgorod Regional pharmacy 8,6 
6.  Health Committee of St. Petersburg 6,4 
7.  
State Unitary Enterprise 
“Medical technology and pharmacy of Tatarstan” 
5,5 
8.  Ministry of Health of the Sverdlovsk Region 3,5 
9.  
State Budgetary Healthcare Institution (Moscow State 
Oncological Hospital No. 62) 
3,4 
10.  
State Budgetary Healthcare Institution “Saint-Petersburg clinical 




The first place in this rating is occupied by the Ministry of Health of the Russian 
Federation, which accounted for almost 25% of the total volume of purchases of medicines in 
2019. For the first time in recent years, the TOP customers included medical and preventive 
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institutions, the leading positions are occupied by cancer centers in Moscow and St. Petersburg 
with purchases of 3 billion rubles. 
 
Summing up the results of the analysis, it can be stated that in 2017 there was a decrease in 
the volume of auctions held compared to 2016. This decrease was caused by a large number of 
tenders drawn at the end of 2016 in anticipation of changes in the rules of bidding from January 1, 
2017, which immediately affected a sharp increase in all market indicators in 2016 compared to 
2015. In 2017, the situation stabilized, so in comparison with 2016, we can observe a decrease in 
the main volumes and the number of participants, including distribution companies. 
 
In 2018, the situation began to stabilize and a slight increase in total purchases began. In 
2019, the volume of procurement of medicines increased due to additional funding of federal 
programs and the launch of the project "Fight against cancer". We can note the growth of 23%, 
especially in the segment of the budget market-the Federal Program of 7(12) nosologies by 36%, 
"preferential purchases" by 12% and the clinical sector by 46%, with stabilization in other market 
segments. The increase in funding is mainly due to the purchase of antitumor drugs (ATC group 
L), as well as the purchase of systemic antimicrobial agents (ATC group J). 
 
The unfolding of the program to combat cancer diseases also affected the picture by other 
criteria, namely, that the rating of customers included the medical and preventive institutions 
themselves, mainly republican and regional cancer dispensaries, and the leaders of the former 
cancer centers of Moscow and St. Petersburg: State Budgetary Healthcare Institution (Moscow 
State Oncological Hospital No. 62) and State Budgetary Healthcare Institution “Saint-Petersburg 
clinical scientific and practical center for specialized types of medical care (oncological)”. In 
addition, in 2019, several expensive original antitumor drugs were allowed to enter the Russian 
market, which immediately affected the increase in the total amount of purchases. 
 
If we talk about the specifics of budgeting in 2019, the main factor here is the cancellation 
of a significant number of auctions in the first half of the year. By the end of 2019, the situation 
has leveled off a little, but the situation is not fundamentally changing. It was affected by the fact 
that most of the suppliers of medicines refused to go to auctions with a low initial maximum 
purchase price. First of all, this was negatively affected by the introduction of a new payment 
scheme from 01.2019. In the country of canceled applications, the share of all received 
applications was more than 25%, with higher rates for individual medicines. 
 
About 10% of the published schedule plans failed to be drawn in 2019, despite the fact that 
some of these auctions were announced repeatedly. 
 
This situation with the cancellation of auctions inevitably affected the supply of medicines 
with interruptions, which was further aggravated by the introduction of mandatory labeling in 
2020. All the leading suppliers remained in their places, but in general the situation is very, very 
unstable. The top line of the rating is continuously headed by JSC Pharmstandard and JSC R-
Pharm. 
 
In 2019, the trend of the last five years continued in the budget market of medicines. Due 
to national programs, the market volumes are growing, the main participants of this market are in 




The health care system has recently faced more and more new challenges, both of a global nature 
and of a specific and systemic nature. Global challenges and problems are not only the emergence 
of new diseases and viruses, including COVID-19, but also the ongoing changes in the structure of 
the population's morbidity, pushing for the creation of more and more new drugs with an 
increasing demand for medicines and medical services. Public procurement is a stable and 
predictable segment of the pharmaceutical market in Russia, and the system of public procurement 
of medicines is a system-forming component of the drug supply of the population, which 
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implements legally established guarantees of the availability and quality of medical care. Further 
development of the procurement system acts as a locomotive for improving the efficiency of 
public funds management, which is one of the conditions for the growth of socio-economic 
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